Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Buy” by Brokerages
02:10am, Monday, 19'th Jan 2026
Shares of Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eighteen brokerages that are currently covering the firm, MarketBeat repo
Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
07:15am, Wednesday, 14'th Jan 2026
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down
Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:46pm, Monday, 12'th Jan 2026
Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
06:01pm, Friday, 09'th Jan 2026
COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascen
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
04:01pm, Thursday, 08'th Jan 2026
– Once-weekly TransCon ® CNP and TransCon ® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 05'th Jan 2026
COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference
Braun Stacey Associates Inc. Makes New $18.68 Million Investment in Ascendis Pharma A/S $ASND
03:36am, Friday, 02'nd Jan 2026
Braun Stacey Associates Inc. purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) during the third quarter, according to the company in its most recent filing with the Securities and
ARS Investment Partners LLC Decreases Stock Position in Ascendis Pharma A/S $ASND
03:18am, Thursday, 25'th Dec 2025
ARS Investment Partners LLC reduced its holdings in shares of Ascendis Pharma A/S (NASDAQ: ASND) by 16.3% in the undefined quarter, according to its most recent 13F filing with the Securities and Exch
Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of “Buy” by Analysts
01:28am, Thursday, 25'th Dec 2025
Shares of Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) have been given a consensus rating of "Buy" by the seventeen research firms that are currently covering the stock, MarketBeat.com reports
Vanguard Health Care Fund's Strategic Moves: Spotlight on AbbVie Inc
04:01pm, Friday, 19'th Dec 2025
Exploring the Fund's Recent Portfolio Adjustments Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the third quarter of 2
Here's My Prediction For Who Could Acquire Ascendis Pharma
03:18am, Monday, 15'th Dec 2025
Ascendis Pharma is rated a cautious buy amid acquisition speculation, robust revenue growth, and a pivotal FDA decision on TransCon CNP. Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, n
High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth
03:45am, Thursday, 11'th Dec 2025
The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to
Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ
01:54pm, Monday, 08'th Dec 2025
The Investment Committee give you their top stocks to watch for the second half.
Ascendis: Q3 Results Validate The TransCon Platform
04:48am, Friday, 05'th Dec 2025
Ascendis Pharma has achieved operational profitability, driven by YORVIPATH's rapid adoption and strong Q3 2025 revenues of €213.6 million. ASND's robust cash position (€539 million) and self-sust
